HALO

Halozyme Therapeutics Stock Price

28.97
-0.30 (-1.02%)
Upgrade to Real-Time
Afterhours (Closed)
28.97
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Halozyme Therapeutics Incorporated HALO NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
-0.30 -1.02% 28.97 28.61 29.48 29.19 29.27 20:00:00
Bid Price Ask Price Spread Spread % News
27.00 32.25 5.25 16.28% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
8,120 745,592 $ 29.05 $ 21,661,441 1,192,473 12.71 - 29.87
Last Trade Time Type Quantity Stock Price Currency
16:45:09 priorref 14,805 $ 28.97 USD

Halozyme Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.93B 135.81M 120.78M $ 195.99M $ -102.52M -0.50 -38.38
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Halozyme Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HALO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week27.5129.635426.6728.49921,2751.465.31%
1 Month28.0229.8726.2528.04933,7800.953.39%
3 Months23.6729.8722.1125.721,242,0695.3022.39%
6 Months19.7329.8712.7121.911,502,5049.2446.83%
1 Year16.7129.8712.7120.051,395,45512.2673.37%
3 Years13.0529.8711.4118.491,089,44315.92121.99%
5 Years22.146629.876.9615.581,215,1496.8230.81%

Halozyme Therapeutics Description

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.